DrugPatentWatch Database Preview
Pertuzumab - Biologic Drug Details
» See Plans and Pricing
Summary for pertuzumab
| Tradenames: | 1 |
| Patents: | 212 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for pertuzumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for pertuzumab |
Recent Clinical Trials for pertuzumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Breast International Group | Phase 2 |
| Jules Bordet Institute | Phase 2 |
| Institut Curie | Phase 2 |
Recent Litigation for pertuzumab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
| Genentech, Inc. v. Amgen Inc. | 2018-06-21 |
| Genentech, Inc. v. Celltrion, Inc. | 2018-01-11 |
Pharmacology for pertuzumab
| Mechanism of Action | HER2/Neu/cerbB2 Antagonists |
Patent Text Search: US Patents for pertuzumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Celgene Corporation (Summit, NJ) | 2039-02-26 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2025-01-21 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2025-05-20 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Hoffmann-La Roche Inc. (Nutley, NJ) | 2025-08-12 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for pertuzumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016042164 | Start Trial |
| Portugal | 2281006 | Start Trial |
| Canada | 2859721 | Start Trial |
| Hong Kong | 1198332 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013063702 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for pertuzumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 02030011 | Spain | Start Trial | PRODUCT NAME: LAROTRECTINIB Y/O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARTICULARMENTE SULFATO DE LAROTRECTINIB QUE INCLUYE HIDROGENOSULFATO DE LAROTRECTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1385; DATE OF AUTHORISATION: 20190919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1385; DATE OF FIRST AUTHORISATION IN EEA: 20190919 |
| 2020000012 | Germany | Start Trial | PRODUCT NAME: LAROTRECTINIB UND/ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919 |
| C00150 | Luxembourg | Start Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
| 20/009 | Ireland | Start Trial | PRODUCT NAME: LAROTRECTINIB AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REGISTRATION NO/DATE: EU/1/19/1385 20190923 |
| 2015 | Austria | Start Trial | PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
